Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Wednesday, April 24, 2019
Show Filter
8:30am - 9:00am 30 mins
Registration & Networking Breakfast
9:00am - 9:15am 15 mins
Opening Remarks
9:15am - 9:45am 30 mins
Opening Keynote Address: Advances in cancer research at Harvard Medical School

Hear about what is happening at Harvard Medical School and where they are headed for future endeavors.

  • Keynote Speaker George Daley, M.D., Ph.D. - Dean of the Faculty of Medicine, Harvard Medical School
9:45am - 10:15am 30 mins
Assessing the Value of Innovation in Oncology

Examine the current obstacles in pricing, reimbursement, access and the healthcare & life sciences infrastructure. What is the current “state of play”? And perhaps most importantly, understand the changes in outcome for patients and the patient perspective.  

  • Contributor Mitch Higashi - Vice President, Health Economics & Outcomes Research, Bristol-Myers Squibb
  • Contributor Deborah Morosini, M.D., MSW - Vice President of Clinical Affairs and Patient Engagement, Loxo Oncology
10:15am - 10:45am 30 mins
Fireside Chat: Breakthroughs in Novel Oncology Drug Development

Examine & Understand the impact of the growing industry pipeline, the evolution of clinical trial landscape and access to available real-world data on Oncology & therapeutic development

  • Contributor Bhavesh Ashar - Senior VP and General Manager Oncology, Bayer Pharmaceuticals
  • Contributor Marion Dorsch, Ph.D. - Chief Scientific Officer, Blueprint Medicines
  • Contributor Nello Mainolfi, Ph.D. - Founder and Chief Scientific Officer, Kymera Therapeutics
10:45am - 11:15am 30 mins
Networking Break
11:15am - 11:30am 15 mins
Strategic Immuno-Oncology Collaboration: Spotlight on Tango Therapeutics

A look at a creative global collaboration to develop & commercialize Immuno-Oncology treatments. 

  • Contributor Shakti Narayan, Ph.D. - CBO, Tango Therapeutics
11:30am - 12:00pm 30 mins
Therapeutic Market Focus: Immuno-Oncology
  • Contributor Pamela Contag, Ph.D. - Chief Executive Officer, BioEclipse Therapeutics
  • Contributor Zhen Su, M.D. - SVP & CMO, EMD Serono, North America
  • Moderator Arthur Krieg, M.D. - Founder & CSO, Checkmate Pharmaceuticals
12:00pm - 12:30pm 30 mins
Keynote: A Survivor's Story
  • Contributor Thomas "Tommy" Cleary - Patient Advocate, Student
12:30pm - 1:30pm 60 mins
Networking Lunch
1:30pm - 2:00pm 30 mins
The Evolving Role of Biomarkers & Diagnostics

Understand how diagnostics are enabling a more targeted approach to treat an increasing number of cancers. 

  • Contributor Andrew Beck, M.D., Ph.D. - CEO, PathAI
  • Contributor Gaurav Singal, M.D. - Chief Data Officer, Foundation Medicine
  • Moderator Elizabeth O'Day, Ph.D. - CEO & Founder, Olaris Therpeutics
2:00pm - 2:30pm 30 mins
New Target Spaces: What's beyond IO?
  • Contributor Stewart Fisher, Ph.D. - CSO, C4 Therapeutics, Inc.
  • Contributor Shinichiro (Shin) Fuse, Ph.D. - Partner, MPM Capital
  • Contributor Jennifer Petter, Ph.D. - Founder & CSO, Arrakis Therapeutics
  • Moderator Michael Zinda - Executive Vice President, Head of Research and Development, Repare Therapeutics
2:30pm - 2:45pm 15 mins
Spotlight- AI & Drug Discovery

How do you separate the hype from reality in today Drug Discovery? Cloud Pharmaceuticals is the leader of AI-based (augmented by data mining and computational chemistry) drug design and development. We will showcase here AI deployment and automation while maintaining chemical information that is crucial for drug discovery.

  • Contributor Shahar Keinan - CEO and Co-Founder, Cloud Pharmaceuticals
2:45pm - 3:15pm 30 mins
Keynote Chat: Reinventing oncology through AI to improve outcomes, accelerate learning, and streamline drug development.

Clinical oncology is in crisis. Patients and physicians are
overwhelmed by a tsunami of research findings, conflicting expert
opinions, and a shortage of actionable data. Meanwhile trials cost too
much, take too long, and are too narrowly focused. Individual outcomes
vary widely and too many trials compete for too few patients. Learn
how AI can help bio-pharma slash the time and cost of developing
drugs, physicians make better decisions, and patients achieve superior
outcomes.

  • Keynote Speaker Marty Tenenbaum, Ph.D. - Founder and Chairman, Cancer Commons; xCures
3:15pm - 3:45pm 30 mins
Networking Break
3:45pm - 4:15pm 30 mins
Fireside Chat: Personalizing Cancer & Its Treatment

How will customizing treatments to individual needs impact the patient journey and treatment? 

  • Contributor Rangaprasad Sarangarajan, Ph.D. - Chief Scientific Officer & SVP, BERG
  • Contributor Roman Yelensky, Ph.D. - EVP & CTO, Gritstone Oncology
  • Moderator Jennifer Wheler, MD, .
4:15pm - 4:45pm 30 mins
Therapeutic Focus: Oncolytic Viruses

Explore how Oncolytic Viruses will increase the chances that patients will respond to Immunotherapies. 

  • Contributor Robert Coffin - Co-Founder & CEO, Replimune
  • Contributor Scott DeWire, Ph.D. - Global Head of Business Development for Cancer Immunology, Boehringer Ingelheim
  • Moderator Theodore (Ted) Ashburn, M.D., Ph.D. - President and CEO, Oncorus, Inc.
4:45pm - 5:15pm 30 mins
Moderated Keynote: Advances in Cancer Research and What lies Ahead

Sit in with Tyler Jacks and Amy Schulman as they discuss some new trends in cancer research and how the convergence of science and engineering is shaping the Koch Institute.

  • Keynote Speaker Tyler Jacks - Director, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
  • Moderator Amy Schulman - Partner, Polaris Partners
5:15pm - 5:30pm 15 mins
Closing Remarks
5:30pm - 6:30pm 60 mins
Cocktail Reception